Clinical Study


Posted Date: May 6, 2021

  • Investigator: Davendra Sohal
  • Specialties: Cancer, Oncology, Pancreatic Cancer
  • Type of Study: Drug

The purpose of this study is to determine if neoadjuvant therapy to increases resection rate for pancreatic adenocarcinoma. Chemotherapy will begin with FOLFIRINOX - a standard regimen used in pancreatic cancer treatment, consisting of 5-fluorouracil, irinotecan and oxaliplatin. Patients will undergo radiation therapy if recommended. Pancreatectomy should occur within 4 to 8 weeks after the last dose of preoperative chemotherapy


Diagnosis Of Pancreatic Carcinoma Or Adenocarcinoma Confirmed By Tissue, Resectable Or Borderline Resectable Primary Tumor, Ecog 0-1, Adequate Organ And Marrow Function As Defined In Protocol, No Uncontrolled Intercurrent Illness Or Comorbidities That Would, In The Opinion Of The Treating Physician, Prevent Receipt Of Standard Of Care Chemotherapy, Radiation Or Surgery.


Pancreatic Cancer, Adenocarcinoma

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.